Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Other Non-Current Liabilities (2022 - 2025)

Historic Other Non-Current Liabilities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $11.5 million.

  • Phathom Pharmaceuticals' Other Non-Current Liabilities rose 697.67% to $11.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 697.67%. This contributed to the annual value of $11.5 million for FY2024, which is 1855.67% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $11.5 million for Q3 2025, which was up 697.67% from $11.5 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Other Non-Current Liabilities high stood at $11.5 million for Q4 2024, and its period low was $7.5 million during Q1 2022.
  • Over the past 4 years, Phathom Pharmaceuticals' median Other Non-Current Liabilities value was $9.7 million (recorded in 2023), while the average stood at $9.3 million.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first changed by 0.0% in 2023, then skyrocketed by 4333.33% in 2024.
  • Phathom Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $7.5 million in 2022, then grew by 29.33% to $9.7 million in 2023, then increased by 18.56% to $11.5 million in 2024, then changed by 0.0% to $11.5 million in 2025.
  • Its Other Non-Current Liabilities stands at $11.5 million for Q3 2025, versus $11.5 million for Q2 2025 and $11.5 million for Q1 2025.